Could specialised diet help with long-term COVID?
Washington DC, US: A new clinical trial is investigating whether a diet meant to reduce inflammation can be beneficial for those with long COVID.
Approximately 7 per cent of Americans have had protracted COVID, which is characterised by a variety of chronic health problems that occur after infection and recovery from COVID-19. Fatigue, brain fog, headaches, chest pain, heart palpitations, and other symptoms may occur.
There is currently no established cure for the illness, and the mechanisms that produce it are unknown.
The premise of the trial revolves around recent research indicating that long COVID may be caused by a hyper inflammatory response that becomes activated during COVID-19 as the body fights off the virus but, in some people, does not recede even after the infection has passed. High inflammation levels in the body can lead to organ damage and other health problems.
"We are examining if food choice can quiet the body's inflammatory response and in doing so, effectively minimize or curtail long COVID symptoms," said Adupa Rao, MD, an investigator of the clinical trial and medical director of the Keck Medicine Covid Recovery Clinic.
The study will examine the anti-inflammatory effect of a low-carbohydrate diet to lower blood glucose (sugar) levels in combination with a medical food that raises blood ketone levels. Ketones, including beta-hydroxybutyrate, the active ketone in this food, are chemicals the body produces to provide energy when the body is low on carbohydrates and sugars. A low-carb diet and ketones have both been associated with reduced inflammation in the body.
Researchers plan to enrol 50 long COVID patients being treated by Keck Medicine's Covid Recovery Clinic. Half the individuals will receive a 30-day dietary intervention and half will not. At the end of the month, researchers will determine how patients tolerated the regimen as well as compare inflammatory markers and long COVID symptoms between the two groups of patients.
If the nutritional intervention is tolerated well by patients and improves their health issues, researchers plan to expand the clinical trial to a larger population.
"Research like ours is vital to expand our understanding of long COVID and ultimately help identify effective treatments to improve patients' quality of life," said the principal investigator of the clinical trial, Nuria Pastor-Soler, MD, PhD, who is also an associate professor of medicine at the Keck School of Medicine of USC. "The results of this trial will hopefully move us closer to potential solutions."
